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Summary
Background Recreational drug use in men who have sex with men (MSM) is of concern because it might be linked to 
the transmission of HIV and other sexually transmitted infections. Evidence about drug use in HIV-diagnosed MSM 
in the UK is limited by representativeness of the study populations. We describe patterns of drug use and associations 
with sexual behaviours in HIV-diagnosed MSM in the UK.
Methods We used data from the cross-sectional ASTRA study, which recruited participants aged 18 years or older with 
HIV from eight HIV outpatient clinics in the UK between Feb 1, 2011, and Dec 31, 2012. We examined data for MSM, 
assessing the prevalence of recreational drug use and polydrug use in the previous 3 months and associations with 
sociodemographic and HIV-related factors. We examined the association of polydrug use with measures of condomless 
sex in the previous 3 months and with other sexual behaviours.
Findings Our analysis included data for 2248 MSM: 2136 (95%) were gay, 1973 (89%) were white, 1904 (85%) were on 
antiretroviral treatment (ART), and 1682 (76%) had a viral load of 50 copies per mL or lower. 1138 (51%) used 
recreational drugs in the previous 3 months; 608 (27%) used nitrites, 477 (21%) used cannabis, 460 (21%) used erectile 
dysfunction drugs, 453 (20%) used cocaine, 280 (13%) used ketamine, 258 (12%) used 3,4-methylenedioxy-N-
methylamphetamine (MDMA), 221 (10%) used gamma-hydroxybutyrate or gamma-butyrolactone, 175 (8%) used 
methamphetamine, and 162 (7%) used mephedrone. In the 1138 individuals who used drugs, 529 (47%) used three or 
more drugs and 241 (21%) used ﬁ ve or more. Prevalence of injection drug use was 3% (n=68). Drug use was 
independently associated with younger age (p<0·0001), not being religious (p=0·001), having an HIV-positive stable 
partner (p=0·0008), HIV-serostatus disclosure (p=0·009), smoking (p<0·0001), evidence of harmful alcohol drinking 
(p=0·0001), and ART non-adherence (p<0·0001).  Increasing polydrug use was associated with increasing prevalence 
of condomless sex (prevalence range from no drug use to use of ﬁ ve or more drugs was 24% to 78%), condomless sex 
with HIV-seroconcordant partners (17% to 69%), condomless sex with HIV-serodiscordant partners (10% to 25%), and 
higher-HIV-risk condomless sex after taking viral load into account (4% to 16%; p≤0·005 for all). Associations were 
similar after adjustment for sociodemographic and HIV-related factors. Methamphetamine was more strongly 
associated with higher-HIV-risk condomless sex than were other commonly used drugs.
Interpretation Polydrug use is prevalent in HIV-diagnosed MSM and is strongly associated with condomless sex. 
Specialist support services for MSM with HIV who use recreational drugs might be beneﬁ cial in the reduction of 
harm and prevention of ongoing transmission of HIV and other sexually transmitted infections.
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Introduction
Recreational drug use is an important public health 
concern in men who have sex with men (MSM) in 
the UK.1,2 Findings from studies done in Europe and the 
USA show that drug use is more prevalent in MSM 
compared with the general population.3–5 Drugs that are 
usually taken in nightclubs and in unlicensed dance 
parties are collectively known as club drugs and 
encompass controlled and non-controlled substances 
including 3,4-methylenedioxy-N-methylamphetamine 
(MDMA, or ecstasy), methamphetamine (crystal meth), 
gamma-hydroxybutyrate (GHB), gamma-butyrolactone 
(GBL), mephedrone, and ketamine.6,7 Although ﬁ ndings 
from many studies in the past 15 years have shown the 
high prevalence of drug use in MSM,4–6 club drug use 
might have increased in this group possibly becoming 
normalised within sexual contexts.1,8 One London club 
drug clinic (a free health service for adult clubbers and 
lesbian, gay, bisexual, and transgender people), for which 
data have been collected since 2005, reports increasing 
use of methamphetamine, mephedrone, and GHB, solely 
in facilitating sex (known as chemsex) in MSM attending 
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the clinic,2 and it has been suggested that the practice of 
injecting recreational drugs at sex parties might be 
increasing in MSM.9,10
A possible changing culture of recreational drug use 
in MSM in the UK might be linked to increased sexual 
risk behaviours.1 This increase could in turn lead to an 
increase in new sexually transmitted infections (STIs) 
including HIV, the transmission of which is high in 
MSM in the UK (3250 new diagnoses in 2012).11 
Findings from many online and gay-venue-based 
studies in MSM in Europe, Australia, and North 
America have associated use of some drugs (such as 
methamphetamine and erectile dysfunction drugs) 
with sex without a condom (herein referred to as 
condomless sex), including with HIV-serodiscordant 
status partners.5,12–16 Findings from several studies have 
shown HIV-diagnosed MSM to be more likely to use 
almost all types of recreational drugs compared with 
MSM who are HIV-negative or un diagnosed.4,14,17,18 
Polydrug use (use of more than one drug at the same 
time or within the same time period) might indicate a 
more severe substance abuse problem. Findings from 
some studies from the UK and USA suggest that 
polydrug use is particularly prevalent in HIV-positive 
MSM.4,19 Additionally, polydrug use was linked to 
condomless sex with casual partners in a US study of 
HIV-diagnosed MSM surveyed in bars and sex clubs.20 
However, ﬁ ndings relating to HIV-diagnosed MSM 
from online and venue-based studies might have 
restricted generalisability. UK researchers21 reported 
the prevalence of methamphetamine and other 
recreational drug use in a sample of HIV-diagnosed 
MSM from a London HIV clinic between 2002 and 
2003.21 Since then, few studies have assessed patterns 
of recreational drug use and the extent of polydrug use 
from representative samples of HIV-diagnosed MSM 
in the UK.
We describe the prevalence of recreational drug use and 
polydrug use, their association to socio-demographic, 
lifestyle, and HIV-related factors, and their relation with 
condomless sex and other sexual behaviours in HIV-
diagnosed MSM in the UK from the ASTRA (Antiretrovirals, 
Sexual Transmission Risk and Attitudes) study.
Methods
Study design
The ASTRA study has been described elsewhere.22 Brieﬂ y, 
ASTRA recruited men and women aged 18 years or older 
with HIV who were attending eight HIV outpatient 
clinics in the UK between Feb 1, 2011, and Dec 31, 2012.22 
Participants completed a conﬁ dential, self-administered 
questionnaire that sought information about socio-
demographic factors (age, ethnic origin, education, 
employment, housing, ﬁ nancial hardship, religion, HIV-
status, and their stable partner’s HIV status), HIV-related 
factors (date of HIV diagnosis, antiretroviral treatment 
[ART] history, and adherence to ART), lifestyle factors 
(cigarette smoking, evidence of harmful alcohol 
consumption according to the modiﬁ ed World Health 
Organization’s [WHO] AUDIT-C question naire,23 and 
recreational drug use), and sexual behaviour measures. 
Consent to participate included permission to collect 
latest CD4 count and HIV plasma viral load. Men who 
identiﬁ ed as being gay or bisexual, or who reported sex 
with men in the previous 3 months, were classiﬁ ed as 
MSM. The study was approved by the North West London 
REC 2 research ethics committee (ref 10/H0720/70).
Procedures
Participants were asked if they had used recreational 
drugs in the past 3 months and if so which ones. 
Recreational drugs included the following: acid, lysergic 
acid diethylamide (LSD), or magic mushrooms (all 
grouped as psychedelics); anabolic steroids; cannabis 
(marijuana); cocaine (coke); crack; codeine; crystal meth 
(methamphetamine); ecstasy (E); GHB (liquid ecstasy); 
heroin, ketamine (K); khat (chat); mephedrone; morphine; 
opium; poppers (amyl nitrites); speed (amphetamine); 
and erectile dysfunction drugs sildenaﬁ l and tadalaﬁ l. 
Other drugs were coded to the above categories according 
to slang names.24 Polydrug use was assessed by the 
number of diﬀ erent drugs used during the previous 
3 months. Club drugs were deﬁ ned as MDMA, GHB 
(liquid ecstasy) or GBL, ketamine, and mephedrone. We 
did not include methamphetamine in the deﬁ nition for 
club drugs because reports suggest it might be more 
commonly used in private sex parties.1,10,25 Participants 
were asked about injecting recreational drugs and needle 
sharing in the past 3 months.
We deﬁ ned ten sexual behaviour measures in the 
previous 3 months (unless otherwise stated): any anal or 
vaginal sex, condomless sex (anal or vaginal sex without a 
condom), condomless sex with a seroconcordant (HIV-
diagnosed) partner, condomless sex with a serodiscordant 
partner (of unknown or HIV-negative status), higher-HIV-
risk condomless sex with a serodiscordant partner (if the 
participant was either not on ART, had latest HIV viral load 
greater than 50 copies per mL, or had a new STI diagnosis 
in the previous 3 months), new STI diagnosis (syphilis, 
gonorrhoea, chlamydia, lymphogranuloma venereum, 
new hepatitis B and C, genital herpes, genital warts, 
trichomonas, non-speciﬁ c urethritis, non-gonoccocal 
urethritis), group sex (with more than one person on the 
same occasion), used the internet to ﬁ nd sexual partners, 
agreement to the statement “I am less likely to use a 
condom with a casual partner (no recall period)”, and 
number of new sexual partners in the previous year.
Statistical analysis
Our analysis includes HIV-diagnosed MSM only. First, 
we assessed prevalence of any recreational drug use, 
and use of one, two, three, four, or ﬁ ve or more types of 
drug in the past 3 months, and examined patterns of 
drug use according to number of drugs used. Second, 
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we examined the association of sociodemographic, 
HIV-related, and lifestyle factors with any recreational 
drug use (dependent variable); in recreational drug 
users, we assessed factors associated with use of four or 
more drugs versus one to three drugs. We examined 
crude associations with χ² tests, and used modiﬁ ed 
Poisson regression models with robust error variances26 
to produce prevalence ratios (PRs) with 95% CIs. 
Factors with p<0·15 in univariable analysis were 
considered in multivariable models; factors with 
p<0·05 were retained in the ﬁ nal model. Third, we 
examined associations of recreational drug use and 
polydrug use (none, one, two, three, four, or ﬁ ve or 
more drugs) with each of the ten measures of sexual 
behaviour (dependent variables). We assessed 
unadjusted associations with χ² tests and adjusted (for 
signiﬁ cant sociodemographic and HIV-related factors) 
associations with modiﬁ ed Poisson regression.
Because some recreational drugs are reported to be 
used solely in a sexual context,9,10 the analysis of 
associations between polydrug use and measures of 
condomless sex was repeated in the subgroup of MSM 
who reported any anal or vaginal sex in the past 
3 months. Within this subgroup, we further examined 
the adjusted association of speciﬁ c drugs and club drugs 
with higher-HIV-risk condomless sex with a 
serodiscordant partner with multivariable modiﬁ ed 
Poisson models. For each drug, the reference category 
was no recreational drug use, and the remaining two 
categories were use of the speciﬁ c drug and use of any 
other recreational drug. We adjusted all multivariable 
Poisson models for clinic centre. We used Stata SE 
(version 12.0) for all statistical analyses. 
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
During the study period 5112 HIV-diagnosed men and 
women were invited to participate, of whom 4200 (82%) 
consented to take part. 3258 patients completed the 
questionnaire (response rate 64% of the 5112 individuals 
approached). 2248 (69%) of these patients were MSM, 2136 
(95%) of whom identiﬁ ed as gay and 112 (5%) identiﬁ ed as 
bisexual. 1973 (89%) identiﬁ ed as white, 983 (45%) were 
educated to university degree, and 1357 (62%) were 
employed. Median age was 46 years (IQR 39–51) and 
median time since HIV diagnosis was 10 years (5–16). 
Overall, 1904 (85%) were on antiretroviral treatment, of 
whom 1654 (88%) had undetectable viral load (≤50 copies 
per mL) at their most recent test.
1435 men who identiﬁ ed as MSM had anal or vaginal 
sex in the previous 3 months; 1402 (98%) had anal sex 
with men only, 12 (<1%) had anal or vaginal sex with 
women only, and 21 (2%) had both anal sex with men and 
anal or vaginal sex with women.
1138 MSM (50·6%, 95% CI 48·6–52·7) reported 
recreational drug use in the previous 3 months. The 
most commonly used drugs were nitrites, cannabis, 
erectile dysfunction drugs, cocaine, ketamine, MDMA, 
GHB or GBL, methamphetamine, and mephedrone 
(ﬁ gure 1). The prevalence of use of club drugs was 22% 
(n=503), and including methamphetamine the 
prevalence was 24% (n=540). When excluding nitrites, 
the overall prevalence of recreational drug use was 44% 
(1000 of 2248 individuals).
Figure 1: Recreational drug use in the past 3 months in HIV-diagnosed men who have sex with men
(A) Prevalence of recreational drug use in 2248 individuals. (B) Type of drug according to number of drugs used in 
1138 individuals who used at least one drug. GHB=gamma-hydroxybutyrate. GBL=gamma-butyrolactone. 
MDMA=3,4-methylenedioxy-N-methylamphetamine. 
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Recreational drug use in 2248 HIV-diagnosed men who have sex with men Use of four or more recreational drugs in 1138 HIV-diagnosed men who 
have sex with men who used at least one drug
n/N (%) Univariate 
p value 
Adjusted 
prevalence ratio* 
(95% CI;
n/N=1138/2248)
Final model 
p value†
n/N (%) Univariate 
p value 
Adjusted 
prevalence ratio*
(95% CI; 
n/N=353/1138)
Final model 
p value†
Age at recruitment, years <0·0001† 0·0018†
<30 67/107 (63%) ·· 1·7 (1·3–2·3) ·· 34/67 (51%) 1·7 (1·0–3·0) ··
30–39 306/496 (62%) ·· 1·7 (1·3–2·1) ·· 106/306 (35%) 1·2 (0·7–2·0) ··
40–49 485/935 (52%) ·· 1·5 (1·1–1·9) ·· 144/485 (30%) 1·1 (0·6–1·8) ··
50–59 208/504 (41%) ·· 1·2 (0·9–1·5) ·· 49/208 (24%) 0·8 (0·5–1·4) ··
≥60 44/150 (29%) 1·00 <0·0001† 12/44 (27%) 1·00 0·002†
Ethnic origin 0·201 0·598
White 1006/1973 (51%) ··  ·· 309/1006 (31%) ··  ··
Black African 7/23 (30%) ··  ·· 1/7 (14%) ··  ··
Black Other 29/53 (55%) ··  ·· 11/29 (38%) ··  ··
All other 77/160 (48)  ·· ·· 26/77 (34%)  ·· ··
Education 0·622 0·009
University degree or above 494/983 (50%) ··  ·· 174/494 (35%) 1·2 (1·0–1·6) ··
No qualiﬁ cations or up to 
A levels (or equivalent)
627/1222 (51%) ··  ·· 175/627 (28%) 1·00 0·009
Employment 0·0001 0·016
Employed 721/1357 (53%) ·· ·· 247/721 (34%) ·· ··
Unemployed 166/320 (52%) ·· ·· 45/166 (27%) ·· ··
Other (retired, carer, 
disabled, student)
227/520 (44%) ·· ·· 57/227 (25%) ·· ··
Housing 0·003 0·740
Owner 430/913 (47%) ·· ·· 131/430 (31%) ·· ··
Renting 612/1127 (54%) ·· ·· 195/612 (32%) ·· ··
Other (homeless, staying with 
friends, work accommodation)
82/174 (47%) ·· ·· 23/82 (28%) ·· ··
Money for basic needs 
(ﬁ nancial hardship)
0·326 0·159
Always 579/1151 (50%) ·· ·· 195/579 (34%) ·· ··
Mostly or sometimes 446/886 (50%) ·· ·· 127/446 (28%) ·· ··
Never 100/178 (56%) ·· ·· 28/100 (28%) ·· ··
Religious‡ <0·0001 0·055
Yes 425/947 (45%) 1·00 ·· 118/425 (28%) 1·00 ··
No 695/1264 (55%) 1·2 (1·1–1·3) <0·0001 231/695 (33%) 1·2 (1·1–1·3) 0·040
Partner’s HIV status <0·0001 0·0031
HIV-positive 303/522 (58%) 1·00 ·· 117/303 (39%) 1·00 ··
HIV-negative or status unknown 321/711 (45%) 0·8 (0·7–0·9) ·· 81/321 (25%) 0·7 (0·5–0·9) ··
No stable partner 514/11015 (51%) 0·9 (0·8–1·0) 0·0008 155/514 (30%) 0·8 (0·6–1·0) 0·003
HIV-status disclosure to friends, 
family, or partners
0·0001 0·590
Disclosed to at least one person 1098/2127 (52%) 1·5 (1·1–1·9) ·· 340/1098 (31%) ·· ··
Not disclosed to anyone 37/113 (33%) 1·00 0·009 13/37 (35%) ·· ··
Evidence of alcohol dependency
(modiﬁ ed WHO AUDIT-C)§
<0·0001 0·416
No 328/785 (42%) 1·00 ·· 96/328 (29%) ·· ··
Yes 810/1463 (55) 1·2 (1·1–1·3) 0·0001 257/810 (32%) ·· ··
Smoking status <0·0001 0·555
Current smoker 519/823 (63%) 1·4 (1·3–1·6) ·· 167/519 (32%) ·· ··
Ex-smoker 335/718 (47%) 1·1 (1·0–1·3) ·· 104/335 (31%) ·· ··
Never smoked 281/687 (41%) 1·00 <0·0001 80/281 (28%) ·· ··
(Table 1 continues on next page)
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Of 1138 MSM who had used recreational drugs, 368 
(32%) used one drug, 241 (21%) used two, 176 (16%) 
used three, 112 (10%) used four, and 241 (21%) used ﬁ ve 
or more. In the 368 MSM who used only one drug in the 
past 3 months, 138 (38%) used nitrites, 133 (36%) used 
cannabis, and 44 (12%) used cocaine (ﬁ gure 1). 241 MSM 
used two drugs in the past 3 months; of the 477 
responses for use of two drugs, 128 (27%) of responses 
were for nitrites, 104 (22%) were for cannabis, 81 (17%) 
were for erectile dysfunction drugs, and 77 (16%) were 
for cocaine. The proportional use of methamphetamine 
and club drugs increased with the number of drugs an 
individual reported to have taken in the past 3 months 
(ﬁ gure 1). Injecting drug use in the previous 3 months 
was reported by 68 individuals (3·0%, 95% CI 2·4–3·8), 
of whom four (6%) reported sharing injecting 
equipment with a person of unknown HIV serostatus.
Although prevalence of drug use was high across most 
demographic groups, in univariable analysis, recreational 
drug use was associated with younger age, being 
employed or unemployed (compared with being retired, 
a carer, sick or disabled, or a student), rented housing 
(compared with owning a home, living in temporary 
accommodation, or being homeless), not identifying 
with a religion, having an HIV-positive stable partner 
(compared with an HIV-negative or no stable partner), 
disclosing HIV status to anyone else, cigarette smoking, 
and evidence of harmful alcohol drinking (table 1). 
Recreational drug use was signiﬁ cantly associated with 
having a viral load greater than 50 copies per mL and 
with ART use and adherence, being higher in men who 
were not on ART, and those who were on ART and non-
adherent, than in those who were on ART and adherent. 
Drug use was not signiﬁ cantly associated with ethnic 
origin, education, ﬁ nancial hardship, time since HIV 
diagnosis, or CD4 cell count (table 1).
Factors independently associated with recreational 
drug use (p<0·05) were younger age, not identifying with 
a religion, having an HIV-positive stable partner, having 
disclosed HIV status to anyone else, evidence of harmful 
alcohol drinking, current cigarette smoking, not being 
on ART, and non-adherence to ART (table 1).
Recreational drug use in 2248 HIV-diagnosed men who have sex with men Use of four or more recreational drugs in 1138 HIV-diagnosed men who 
have sex with men who used at least one drug
n/N (%) Univariate 
p value 
Adjusted prevalence 
ratio* (95% CI; n/
N=1138/2248)
Final model 
adjusted 
p value†
n/N (%) Univariate 
p value 
Adjusted 
prevalence ratio*
(95% CI; n/
N=353/1138)
Final model 
p value†
(Continued from previous page)
Time since HIV diagnosis 0·071† 0·013†
≤6 months 48/92 (52%) ·· ·· 15/48 (31%) ·· ··
6 months to 2 years 84/149 (56%) ·· ·· 31/84 (37%) ·· ··
2–5 years 189/341 (55%) ·· ·· 69/189 (37%) ·· ··
5–10 years 270/529 (51%) ·· ·· 86/270 (32%) ·· ··
>10 years 510/1067 (48%) ·· ·· 138/510 (27%) ·· ··
On antiretroviral treatment (ART) 0·071 0·017
Yes 947/1904 (50%) ·· ·· 279/947 (30%) ·· ··
No 188/333 (57%) ·· ·· 72/188 (38%) ·· ··
CD4 count (clinical record) 0·072 0·111
>350 cells per μL 956/1859 (51%) ·· ·· 307/956; (32%) ·· ··
≤350 cells per μL 166/359 (46%) ·· ·· 43/166; (26%) ·· ··
Viral load (clinical record) 0·015 0·015
≤50 copies per mL 828/1682 (49%) ·· ·· 241/828 (29%) ·· ··
>50 copies per mL 294/532 (55%) ·· ·· 108/294 (37%) ·· ··
ART use and adherence <0·0001 0·007
On ART and adherent 734/1550 (47%) 1·00 159/588 (27%) ·· ··
On ART and non-adherent¶ 183/289 (63%) 1·3 (1·2–1·4) 117/352 (33%) ·· ··
Not on ART 188/333 (57%) 1·1 (1·0–1·2) <0·0001 72/188 (38%) ·· ··
Data given for those who provided responses on the questionnaire, so diﬀ er from total sample size owing to missing data. Adjusted analyses done for men who have sex with men (MSM) who have complete 
data for all these variable. Unadjusted p values calculated with χ2 test or χ2 test for trend. ART=antiretroviral therapy. All factors with p<0·15 in univariable analysis were considered for inclusion in the 
multivariable model, except for viral load and on ART, because the ART use and adherence variable was included. Factors with p<0·05 were retained in the ﬁ nal model. *Prevalence ratio for multivariable 
modiﬁ ed Poission regression (includes adjustment for clinic). †Wald test from adjusted model; the four p values relating to  age and the two p values relating to time since diagnosis of HIV are test for trend. 
‡Identiﬁ es as belonging to a religion (Christianity, Judaism, Islam, Buddhism, Sikhism, any other). §Evidence of harmful alcohol consumption (that increases the risk of harmful consequences for the user or 
others) deﬁ ned as a score of 8 or greater on the modiﬁ ed AUDIT-C questionnaire. ¶Non-adherence deﬁ ned as: missed one or more ART dose in the past 2 weeks or missed 2 or more days of ART on one or 
more occasions in the past 3 months.
Table 1: Association of sociodemographic, HIV-related, and lifesty le factors with recreational and polydrug use in the past 3 months in HIV-diagnosed men who have sex with men
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In univariable analysis in 1138 MSM who used at least 
one drug, use of four or more drugs versus one to three 
drugs in the past 3 months was associated with: 
younger age, university education, current employment, 
not identifying with a religion, having an HIV-positive 
stable partner, more recent HIV diagnosis, viral load 
greater than 50 copies per mL, not being on ART, and 
ART non-adherence (table 1). In multivariable analysis, 
younger age, university education, not identifying with 
a religion, and having an HIV-positive stable partner 
were still signiﬁ cantly associated with use of four or 
more drugs compared with use of one to three drugs 
(table 1). 
In the previous 3 months, 1435 (64%) of the 
2248 individuals had anal or vaginal sex, 859 (38%) had 
condomless sex, 339 (15%) had such sex with a 
serodiscordant partner, and 156 (7%) had higher-HIV-
risk condomless sex with a serodiscordant partner.
Compared with MSM who did not use drugs in the 
previous 3 months, those who used drugs were more 
likely to report any anal or vaginal sex, condomless sex, 
new STI diagnoses, group sex, searching for sexual 
partners on the internet in the past 3 months, having 
ten or more new sexual partners in the past year, and 
being less likely to use a condom with a casual partner 
(table 2)
With increasing number of recreational drugs used we 
noted striking increases in the prevalence of condomless 
sex and all other sexual behaviour outcomes (table 2). 
These associations were not greatly attenuated after 
adjustment for statistically signiﬁ cant sociodemographic 
and HIV-related factors (ﬁ gure 2). We detected a strong 
association between increasing polydrug use and higher 
prevalence of all types of condomless sex for the 
subgroup of 1435 MSM who reported any anal or vaginal 
sex in the past 3 months (appendix).
We assessed the adjusted association between 
individual drugs and higher-HIV-risk condomless 
serodiscordant sex in MSM who reported any anal or 
vaginal sex in the past 3 months (ﬁ gure 3). Compared 
with MSM who used no drugs, MSM who used 
methamphetamine had the highest prevalence ratio of 
higher-HIV-risk condomless serodiscordant sex, followed 
by the prevalence ratios for club drugs, erectile 
dysfunction drugs, nitrites, and cocaine, which were all 
of a similar magnitude.
Discussion
Our ﬁ ndings show that half of the 2248 HIV-diagnosed 
MSM surveyed had used recreational drugs in the past 
3 months and that about a quarter had used at least 
three types of drugs during that time period. Drug use 
and polydrug use were independently associated with 
younger age, not identifying as religious, and having an 
HIV-positive stable partner. Drug use was also 
associated with disclosure of HIV serostatus, harmful 
alcohol drinking, cigarette smoking, not being on ART, 
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See Online for appendix
and non-adherence to ART. We saw strong and 
consistent associations between increasing numbers of 
drugs used and increasing prevalence of all indicators 
of condomless sex (including high HIV-transmission 
risk condomless sex), group sex, and having multiple 
new sexual partners. However, the overall prevalence of 
higher-HIV-risk serodiscordant condomless sex was 
low (7%).
To the best of our knowledge, ASTRA is the largest 
questionnaire study of HIV-diagnosed individuals in the 
UK to date. We think our study population is 
representative of HIV-diagnosed MSM in the UK 
because the UK has universal access to health care and 
95% of HIV-diagnosed people access specialist services.11 
The response rate (64%) was satisfactory with no 
signiﬁ cant diﬀ erences in viral load or CD4 cell count 
between responders and those who did not respond to 
the questionnaire but who consented to participate.22 A 
further strength of the study is the comprehensive 
information obtained about self-reported polydrug use 
and recent sexual behaviour. Nevertheless, under-
reporting of drug use and speciﬁ c sexual behaviours is 
possible and could have led to underestimation of 
prevalence.
Previous comparable data for recreational drug use 
in HIV-diagnosed MSM in the UK derive 
predominantly from a 2002–03 study that surveyed 
HIV-negative and HIV-positive MSM at gyms and 
outpatient clinics in London;21 prevalence of 
recreational drug use in the previous year in the HIV-
diagnosed outpatient sample (n=388) was 54%.21 When 
comparing use of speciﬁ c drugs in the previous 
3 months in participants from London clinics in the 
ASTRA study (N=1527) to drug use that occurred at 
least once or twice a month in the  2002–03 London 
HIV outpatient sample, we detected evidence of higher 
use of methamphetamine (10% vs 4%), cocaine (23% vs 
14%), and injecting drug use (4% vs 1%), similar 
prevalence for use of ketamine (12% vs 13%) and 
amphetamine (3% vs 2%), and lower prevalence for use 
Figure 2: Adjusted prevalence ratios for the association of polydrug use in the past 3 months with measures of sexual behaviour in 2248 HIV-diagnosed men 
who have sex with men
Ratios are adjusted for age group, education, religion, stable partner’s HIV status, antiretroviral treatment use and adherence, and clinic. Sexual behaviour measures 
have 3-month recall period unless otherwise speciﬁ ed. *Condomless sex with a HIV-serodiscordant partner, and not on antiretroviral treatment or viral load greater 
than 50 copies per mL, or diagnosed with a sexually transmitted infection in the previous 3 months. †No recall period. STI=sexually transmitted infection.
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of MDMA (11% vs 17%).21 This comparison suggests 
changing patterns of drug use in HIV-diagnosed 
MSM, with possible increases in methamphetamine 
and injection drug use. However, comparisons are not 
straightforward because of the diﬀ erent recall periods 
for drug use, potential con founding factors in the 
comparison, and the shortage of data from other 
comparable studies in the UK.
There have been few studies of polydrug use in 
representative samples of HIV-diagnosed MSM in the 
UK (panel). Findings from the London 2002–03 study 
showed that more than 90% of the 49 HIV-diagnosed 
MSM who used methamphetamine during the previous 
year had used at least one other drug during this time 
period. Similarly, more than 80% of the 162 cocaine 
users had used other drugs in the previous year.21 In our 
study the high prevalence of polydrug use in the 
previous 3 months (46% of drug users using three or 
more drugs and 21% using ﬁ ve or more) is concerning, 
especially in view of potential drug-drug interactions, 
such as possible cardiovascular harms from 
simultaneous use of erectile dysfunction drugs and 
nitrites,27 intensiﬁ cation of the toxic eﬀ ects of GHB 
when consumed with alcohol,28 and the potential for 
polydrug use to interfere with the eﬀ ectiveness of 
antiretroviral drugs.28 Although we saw that recreational 
drug use was associated with non-adherence to ART 
and lower prevalence of suppressed viral load, 87% of 
HIV-diagnosed MSM on ART who used recreational 
drugs, and 83% of those on ART who used ﬁ ve or more 
drugs, had suppressed viral load, showing that 
recreational drug use is not incompatible with good 
ART adherence.
In our study, recreational drug use and polydrug use 
were associated with being sexually active, and more 
strongly associated with all measures of condomless 
sex. Although a minority (15%) of HIV-diagnosed 
MSM reported sero discordant condomless sex, and 
fewer (7%) fulﬁ lled our criteria for higher-HIV-risk 
serodiscordant condom less sex, it was evident that 
increasing polydrug use was associated with increases 
in prevalence of serodiscordant condomless sex, and 
speciﬁ cally higher-HIV-risk condom less sex. In men 
who reported anal or vaginal sex in the past 3 months, 
meth amphetamine had the strongest association with 
higher-HIV-risk sero discordant condom less sex. 
Findings from previous cross-sectional and longi-
tudinal studies have shown associations between use 
of meth amphetamine and serodiscordant condomless 
sex in HIV-diagnosed MSM,6,21 although none has 
incorporated measures of viral load.30  Additionally, 
results from a US cohort of MSM showed that use of 
methamphetamine was independently associated with 
HIV-seroconversion during follow-up.29Risk of HIV 
transmission is low when the HIV-positive partner is 
adherent to ART with undetectable viral load in the 
absence of STIs,31 in line with available data for the risk 
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Figure 3: Adjusted prevalence ratios for the association of use of speciﬁ c 
drugs in the past 3 months with higher-HIV-risk condomless sex with a 
serodiscordant partner
Data from 1435 HIV-diagnosed men who have sex with men who reported 
any anal or vaginal sex in the past 3 months. Adjusted for age group, religion, 
antiretroviral treatment use and adherence, and clinic. Higher-HIV-risk sex is 
deﬁ ned as condomless sex plus: not on antiretroviral treatment, latest viral 
load greater than 50 copies per mL, or new diagnosis of a sexually transmitted 
infection in the previous 3 months. *Ecstasy, ketamine, mephedrone, and 
gamma-hydroxybutyrate or gamma-butyrolactone.
Panel: Research in context
Systematic review
We searched PubMed and Embase for articles published in English (Jan 1, 1996, to 
July 31, 2014) using the following MeSH headings in any ﬁ elds: “recreational drugs” or 
“street drugs” or “illicit drugs” or “designer drugs” or “controlled substances” or 
“counterfeit drugs” and “men who have sex with men” or “gay” and “sexual behaviour” 
and “HIV”. We identiﬁ ed cross-sectional studies based on venue-based, online, and 
clinic-based samples, of recreational drug use in men who have sex with men (MSM) in 
the USA, Australia, Canada, and Europe, and longitudinal cohort studies of recreational 
drug use and occurrence of HIV in MSM from the USA.5,16,30 We identiﬁ ed two small 
qualitative studies of MSM in the UK who use recreational drugs in a sexual context, 
irrespective of HIV-serostatus.9,10 One cross-sectional HIV clinic-based study was done 
in 2002–03 in HIV-diagnosed individuals in the UK that examined associations with 
sexual behaviours, such as condomless sex with casual partners and looking for sex on 
the internet.21
Interpretation
To the best of our knowledge, ASTRA is the largest questionnaire study of HIV-
diagnosed individuals in the UK, accounting for about 5% of all HIV-diagnosed MSM in 
the UK. Our study includes comprehensive information about the extent of polydrug 
use, which has not been reported before in the UK. We measured condomless sex with 
HIV-seroconcordant, HIV-serodiscordant or unknown status partners, and condomless 
sex with serodiscordant partners accounting for viral load, which has not previously 
been examined. Our ﬁ ndings show that recreational drug use and polydrug use are 
prevalent, and strongly associated with condomless sex and multiple new sexual 
partners among HIV-diagnosed MSM. These ﬁ ndings draw attention to the importance 
of tailored harm reduction support for MSM who use recreational drugs and to the 
need to address the prevention of HIV and sexually transmitted infection in this group. 
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of transmission during anal sex in MSM.32 However, 
such condomless sex, as well as condomless sex with 
partners known to be HIV-positive, does present a risk 
of transmission of other STIs including hepatitis C 
infection, syphilis, and gonorrhoea. Additionally, since 
2004, the UK has an ongoing lymphogranuloma 
venereum epidemic in MSM, of which most cases are 
in HIV-diagnosed MSM, among whom reported levels 
of drug use (particularly methamphetamine and 
mephedrone use) are high.33
The diﬃ  culties in attributing a causal relation to the 
associations between recreational drug use and higher-
risk sexual behaviours in cross-sectional studies have 
been well documented.34 However, irrespective of causal 
attributions, our ﬁ ndings show that polydrug use and 
condomless sex are inextricably linked in HIV-
diagnosed MSM in the UK, and that polydrug users are 
likely to be a group at especially high risk for trans-
mission of HIV and other STIs. A need exists for 
longitudinal, episode-level studies focusing on drug 
use during episodes of condomless sex in the same 
individual, which could provide important information 
about temporality and causality.
Improved understanding of the underlying drivers of 
polydrug use in HIV-diagnosed MSM is needed in 
order to reduce health harms. Cross-agency col-
laboration between HIV treatment and substance 
misuse services might be beneﬁ cial in providing 
tailored, judgment-free harm reduction advice and 
support to HIV-diagnosed MSM who use recreational 
drugs, and in addressing HIV and STI prevention 
issues in this group. Peer-led interventions might also 
be productive in outreach services for HIV-diagnosed 
men who are polydrug users and have multiple sexual 
partners. National STI and HIV prevention strategies 
should address recreational drug use.
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